Strides Shasun’s wholly owned subsidiary -- Strides Pharma Global -- has received approval for Piroxicam capsules 10mg and 20mg from the United States Food & Drug Administration (USFDA). The product received approval within ten months under the GDUFA regime. The US market for Piroxicam capsules 10mg and 20mg is approximately $11 million. The product will be manufactured at the company’s Oral Dosage Facility at Bangalore and will be marketed by Strides Pharma Inc. in the US Market.
Piroxicam is a non-steroidal anti-inflammatory agent with analgesic and antipyretic activity. Piroxicam is indicated for the symptomatic relief of rheumatoid arthritis, osteoarthritis or ankylosing spondylitis.
Strides Shasun (formerly known as Strides Arcolab) is engaged in manufacturing, sale and export of pharmaceutical products. It offers general tablets, hard gelatin and soft gelatin capsules, sachets, potent drugs and semi-solids.
